Objective: This study tests the usefulness of ceftriaxone combined with ampicillin as an alternative to ampicillin plus gentamicin for the treatment of experimental endocarditis due to Enterococcus faecalis without high-level resistance to aminoglycosides. It also determines whether adding ceftriaxone to ampicillin and gentamicin increases the effectiveness against experimental enterococcal endocarditis resulting from E. faecalis.
Introduction
The combination of penicillin or ampicillin plus an aminoglycoside for 4-6 weeks is recommended for the treatment of enterococcal endocarditis. 1 Nevertheless, prolonged therapy with aminoglycosides carries a risk of nephro-and oto-toxicity, particularly in the elderly, 1 the population most frequently succumbing to this infection. In previous work, our group demonstrated the efficacy of ampicillin plus ceftriaxone for the treatment of experimental endocarditis resulting from Enterococcus faecalis strains highly resistant to aminoglycosides (HLRAg) . 2 This combination could be an attractive therapeutic alternative, having potentially lower toxicity than the standard therapy for E. faecalis endocarditis. The aims of the present study were to evaluate the efficacy of ampicillin plus ceftriaxone in the treatment of experimental endocarditis due to non-HLRAg E. faecalis, and to test the effectiveness of a triple combination, adding ceftriaxone to ampicillin and gentamicin, to see whether in vivo efficacy was increased.
Materials and methods
The study strain was E. faecalis EF91, recovered from a patient with endocarditis. MICs/MBCs were determined using Mueller-Hinton broth and a standard microdilution method following NCCLS guidelines. 3 Qualitative estimation of the synergy between ampicillin, ceftriaxone and gentamicin (bacteriostatic interaction) was obtained using a disc diffusion method (ampicillin 10 µg; gentamicin 30 µg; ceftriaxone 30 µg). 4 In addition, time-kill synergy studies were performed in quintuplicate, following accepted methods, in Mueller-Hinton broth, using an inoculum of 10 7 cfu/mL and an ampicillin concentration of 1 mg/L either alone or in combination with gentamicin (final concentrations Induction of aortic endocarditis, and insertion of a catheter into the inferior vena cava to administer ampicillin, gentamicin and ceftriaxone treatment in New Zealand rabbits (weight: 2-2.1 kg) has been described previously. 5, 6 Forty-eight hours after inducing infection with a 1 mL inoculum containing 10 8 cfu of EF91 strain, a 3 day treatment protocol was started in infected rabbits, randomized into the following treatment groups: control, without treatment; ampicillin 2 g every 4 h, using humanlike (H-L) pharmacokinetics iv; ampicillin 2 g every 4 h H-L iv + gentamicin 1 mg/kg every 8 h H-L iv; ampicillin 2 g every 4 h H-L iv + ceftriaxone 2 g every 12 h H-L iv; and ampicillin 2 g every 4 h H-L iv + ceftriaxone 2 g every 12 h H-L iv + gentamicin 6 mg/kg every 24 h subcutaneously (sc). Intravenous drugs were administered using a computer-controlled infusion pump system (infusion pump, Alice King, Hawthorne, CA, USA) that reproduces human serum pharmacokinetics in rabbits. The pharmacokinetic data for ampicillin, ceftriaxone and gentamicin administered iv to mimic human pharmacokinetics have been published previously, 2,5,6 and are summarized in Table 1 . The pharmacokinetic parameters of gentamicin 6 mg/kg every 24 h sc have also been published. 5 The experimental protocol was approved by the Ethics Committee for Animal Experimentation of Vall d'Hebron Hospitals and the Agricultura, Ramaderia i Pesca Department of the Generalitat de Catalunya.
Six hours after completing the final antibiotic infusion, the animals were killed and colony counts in the vegetations determined, as previously described. 5, 6 Bacterial concentrations in vegetations from the various treatment groups were compared using one-way analysis of variance. Each treatment group was compared with the control group and with each of the other treatment groups using Scheffée's test. P values ≤ 0.05 were considered significant.
Results and discussion
The MICs of ampicillin, gentamicin and ceftriaxone were 0.5, 32 and 64 mg/L, respectively; MBCs were 32, 64 and >256 mg/L. Synergistic and bactericidal effects were obtained with combinations of ampicillin and gentamicin (at 1, 3 or 10 mg/L), and ampicillin and ceftriaxone (at 10, 20 or 40 mg/L) after 4 and 24 h of incubation. Susceptibility studies with agar diffusion techniques showed synergy between ampicillin, gentamicin and ceftriaxone.
Results of therapy for EF91 experimental endocarditis are shown in Table 2 . After 3 days of treatment, bacterial counts were reduced in vegetations of the treated animals compared with the control group (P < 0.05). Combinations of ampicillin with gentamicin or ceftriaxone were more effective than ampicillin alone (P < 0.05). Treatment with ampicillin plus ceftriaxone was as effective as ampicillin plus gentamicin (P not significant). Ampicillin combined with gentamicin and ceftriaxone was not superior to ampicillin plus gentamicin or ampicillin plus ceftriaxone (P not significant).
The objectives of this work were: first, to test the usefulness of ceftriaxone combined with ampicillin as an alternative to the gold standard, ampicillin plus gentamicin, for the treatment of endocarditis caused by an E. faecalis strain with no resistance to β-lactams or aminoglycosides; and second, to determine whether efficacy against this disease increases with use of a triple combination: ceftriaxone, ampicillin and gentamicin. Our results showed that ampicillin plus ceftriaxone was as effective as the treatment of choice (ampicillin plus gentamicin) for experimental endocarditis. The triple combination did not improve on the overall efficacies of the two-drug combinations.
The present in vitro studies demonstrated synergistic activity between ampicillin and ceftriaxone against EF91. A similar synergistic in vitro effect was detected by Mainardi et al., with amoxicillin and cefotaxime. 7 Nevertheless, this combination did not show in vivo efficacy in the treatment of experimental endocarditis resulting from two E. faecalis strains, one with and one without high-level resistance to aminoglycosides. The authors concluded that in vivo efficacy was Table 1 . Pharmacokinetic parameters of ampicillin, gentamicin and ceftriaxone iv in rabbit, human and rabbit H-L a The pharmacokinetic parameters were estimated on the basis of an open one-compartment model. b t 1/2 and k el data are for healthy rabbits treated with ampicillin 100 mg/kg, gentamicin 6 mg/kg and ceftriaxone 50 mg/kg iv. The AUC 0→∞ was calculated from the data for an ideal profile obtained with a C 0 of 80 mg/L for ampicillin, a C 0.5 of 5 mg/L for gentamicin, a C 0 of 256.8 mg/L for ceftriaxone and the k el of each drug in rabbits. c k el , t 1/2 and AUC 0→∞ were obtained from an ideal profile in human serum of ampicillin 2 g, gentamicin 1 mg/kg and ceftriaxone 2 g. d Data for H-L pharmacokinetics of ampicillin 2 g, gentamicin 1 mg/kg and ceftriaxone 2 g. absent because amoxicillin alone was bactericidal in vivo and the period of time during which both antibiotics were present simultaneously and at adequate concentrations to obtain in vivo synergy, was limited. 8 In contrast, our in vivo results show that the combination of ampicillin plus ceftriaxone was as effective as ampicillin plus gentamicin administered in three daily doses. The efficacy of the combination of ampicillin plus ceftriaxone was comparable to the efficacy we found for ceftriaxone 2 g every 12 h H-L combined with ampicillin 2 g every 4 h H-L in the treatment of HLRAg E. faecalis experimental endocarditis. 2 The discrepancies between our results and those reported by Join-Lambert et al. 8 can be attributed to dissimilarities among the experimental variables. The β-lactams in the two studies were different and might have had dissimilar activities against E. faecalis, and our experimental model simulated human kinetics of ampicillin 2 g every 4 h iv and ceftriaxone 2 g every 12 h iv. The relationship between the shape of the β-lactam AUCs and their antimicrobial activity has been established; thus, simulation of human serum pharmacokinetics comes closer to the human clinical situation.
The combination of ampicillin plus ceftriaxone broadens the range of alternative therapies for the treatment of enterococcal endocarditis. Toxicity resulting from aminoglycosides depends mainly on the duration of treatment, the age of the patient and total amount administered. 1 Since enterococcal endocarditis appears generally in older patients, and age is associated with a higher risk of nephrotoxicity from aminoglycosides, 1 these patients may benefit from lesstoxic therapy. Our group recently reported our experience with 20 episodes of enterococcal endocarditis treated with ampicillin combined with ceftriaxone or cefotaxime, including 13 episodes caused by strains with HLRAg and seven resulting from non-resistant strains. 9 Sixteen patients received at least 1 month of cephalosporin therapy and all were cured; only three patients underwent surgery and none developed renal failure. We concluded that the combination of ampicillin plus ceftriaxone or cefotaxime was safe and effective in the treatment of enterococcal endocarditis caused by strains with and without HLRAg.
Enterococcal endocarditis still lacks a completely satisfactory treatment. The standard therapy, ampicillin plus gentamicin, does not cure all cases and its prolonged duration poses a risk to patients.
Effort must be made to find combinations that can cure a higher percentage of cases, and efficacious treatments of a shorter duration. In the present study, the efficacy obtained with the addition of ceftriaxone to the combination of ampicillin plus gentamicin was similar to that of ampicillin combined with gentamicin or ceftriaxone. The triple combination did not improve on the overall efficacies of the twodrug combinations. There is little experience with triple-drug combinations for the treatment of enterococcal experimental endocarditis. Caron et al. 10 found that combined penicillin, gentamicin and vancomycin was effective for experimental endocarditis caused by E. faecium highly-resistant to penicillin and glycopeptides, whereas combined penicillin or vancomycin plus gentamicin was not effective. These authors detected the emergence of a subpopulation resistant to the combination of penicillin plus vancomycin, and this reduced the utility of this combination.
In conclusion, the efficacy of ampicillin and ceftriaxone combined in our experiments was comparable to that of ampicillin plus gentamicin. Since there is a relatively lower risk of nephrotoxicity with ampicillin plus ceftriaxone, this combination could be valuable for treating enterococcal endocarditis resulting from non-HLRAg strains in elderly patients, or in those with previous renal disease or signs of toxicity. Further studies are needed to establish the true efficacy of this therapeutic approach in humans with enterococcal endocarditis. Table 2 . Results of the therapeutic groups of rabbit experimental endocarditis due to the Enterococcus faecalis EF91 strain, using H-L pharmacokinetics a All treatment groups showed a significant reduction of the Log 10 cfu/g (P < 0.05) with respect to the control group. b Treatment groups with combination drugs showed a significant reduction of the Log 10 cfu/g (P < 0.05) with respect to the group treated with ampicillin H-L alone. 
